Paradox Immunotherapeutics Analysis: $10M Raised
What is Paradox Immunotherapeutics?
Paradox Immunotherapeutics develops monoclonal antibody treatments targeting protein misfolding diseases, including amyloidosis. Their proprietary immunotherapy design platform focuses on selectively targeting misfolded proteins while preserving healthy proteins. The company aims to address the healthcare crisis posed by these diseases, which are often considered incurable.
Location
100 College St, Toronto, Ontario M5G 1L5, Canada
Employees
1-10
Founded
2019
Funding Status
Seed
Product Features & Capabilities
- LX-96
- KX-99
- NX-86
Use Cases
Target misfolded proteins in ALS and Alzheimer's; Develop therapies for AL, ATTR, and ALECT2 amyloidosis; Conduct FDA clinical trials for lead candidates; Provide hope for patients with rare diseases; Combat multi-organ failure caused by protein misfolding
Other Considerations
Three pre-clinical stage antibodies with commercial interest; Team includes experts in monoclonal development and protein biochemistry; Addresses a global healthcare crisis affecting 300 people per million worldwide
See something that needs updating? Suggest edits to this profile.